Email a Friend
Printer Friendly
Slashdot It!
Submit to Reddit
Add to Facebook

Girls and children exposed to tobacco smoke benefit more from montelukast (singulair)

May 14, 2008

Girls and children exposed to tobacco smoke respond particularly well to montelukast (Singulair) according to researchers at National Jewish Medical and Research Center. Associate Professor of Pediatrics Nathan Rabinovitch, MD, and his colleagues also identified two biomarkers that may help physicians predict even more precisely which patients will benefit from montelukast.

"These findings will help doctors know in advance which patients are most likely to benefit from montelukast and to tailor an effective treatment regimen for specifically them," said Dr. Rabinovitch.

The study was recently published online and will appear in the June issue of the Journal of Allergy and Clinical Immunology.

Inhaled corticosteroids are considered the first-line treatment for cases of persistent asthma. However, steroids alone do not effectively control asthma in 30 percent to 40 percent of patients and they may have some side effects, especially in children. In those cases, a secondary medication is often used. Montelukast is one such medication.

Montelukast, one of the most widely prescribed medications for asthma and allergies, blocks the action of chemicals called leukotrienes, which contribute to inflammation. However, physicians have found that montelukast is quite variable in its effectiveness, helping some patients but not others. Dr. Rabinovitch and his colleagues set out to better understand its variable effectiveness.

They followed the 27 asthmatic students from the Kunsberg School on the National Jewish campus for five months. The children received daily montelukast or a placebo without any change in their other asthma medications. The primary measure of asthma control was how often children needed to use their short-acting rescue medication albuterol.

Before the children began taking montelukast, researchers found that when leukotriene levels in their urine rose, the children used 20 to 25% more albuterol two days later. Once they began taking montelukast, however, children did not need to take albuterol as often when their leukotriene levels rose. Two groups of children responded particularly well to montelukast: girls and children with high levels of cotinine in their urine, which indicated exposure to secondhand tobacco smoke. Both had statistically significant reduced sensitivity to leukotrienes once they began taking montelukast.

"When looking at a general population of patients, montelukast does not appear to be very effective," said Dr. Rabinovitch. "However, in certain patients, the choice of motelukast may be warranted, particularly in school-age girls and children exposed to tobacco smoke."

Dr. Rabinovitch and his colleagues also found that measuring exhaled nitric oxide, a measure of inflammation in patients' breath, and leukotrienes in their urine, could also help them predict which patients would respond well to montelukast-- those with a high leukotriene/nitric oxide ratio.

"Increasingly we have come to understand that asthma is not just one disease; it is more likely several diseases that present with similar symptoms. Thus different medications are likely to work for different patients," said Dr. Rabinovitch. "It is important that we be more selective and tailor our medication regimen so that each child receives the most safe and effective treatment for their type of asthma."

National Jewish Medical and Research Center

Related Montelukast Current Events and Montelukast News Articles

Long-Acting Beta-Agonists Shown to be Most Effective Step-Up Therapy for Children with Poorly Controlled Asthma
For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments.

ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells.

Drug reduces unscheduled trips to doctor for childhood asthma attacks
Young children with attacks of sporadic, recurring asthma who were treated with the prescription drug montelukast by their parents had fewer unscheduled trips to the doctor, missed less days from school or childcare, and caused their parents to take fewer days off work for their care.

Obesity may affect response to asthma medications
As the nation's collective waistline has swelled in recent decades, rates of asthma diagnoses also have accelerated. Indeed, much research has affirmed a link between the two conditions.

ICS most effective for persistent asthma in children
While both inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRA) have been proven to help control mild-to-moderate persistent asthma in school-age children, a new study shows ICS may be the more effective treatment.

More Montelukast Current Events and Montelukast News Articles

	Montelukast: Webster's Timeline History, 1995 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Montelukast," including when used in literature (e.g. all authors that might have Montelukast in their name). As such, this book represents the largest compilation of timeline events associated with Montelukast when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...
	Recurrent Wheezing Illness in Preschool-Aged Children: Assessment and Management in Primary Care Practice by JTE Multimedia Abstract: Recurrent wheezing is common in preschool-aged children, with 1 in 3 children experiencing at least 1 acute wheezing illness before the age of 3 years. These children represent a diverse group, with some going on to present with asthma at school age and others experiencing complete resolution of symptoms. The primary care physician is faced with a dilemma of when to recommend daily therapy. He or she must also answer parents’ concerns, often expressed as, “Does my child have asthma?” and “Will my child have to take medication the rest of his or her life?” This article presents recent studies and recommendations that can guide the physician in approaching the child and the parent with rational management. The emphasis is on viewing recurrent wheezing as a continuum...
	Rofecoxib, Montelukast Combo Cut Migraines.(Brief Article): An article from: Family Practice News by Sherry Boschert (Author) This digital document is an article from Family Practice News, published by International Medical News Group on July 1, 2001. The length of the article is 376 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Rofecoxib, Montelukast Combo Cut Migraines.(Brief Article) Author: Sherry Boschert Publication: Family Practice News (Magazine/Journal) Date: July 1, 2001 Publisher: International Medical News Group Volume: 31 Issue: 13 Page: 22 Article Type: Brief Article Distributed by Thomson...
	Montelukast reduces wheeze in viral illness. (Study Shows Symptoms Improved).: An article from: Pediatric News by Timothy F. Kirn (Author) This digital document is an article from Pediatric News, published by International Medical News Group on June 1, 2003. The length of the article is 462 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Montelukast reduces wheeze in viral illness. (Study Shows Symptoms Improved). Author: Timothy F. Kirn Publication: Pediatric News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 37 Issue: 6 Page: 5(1) Distributed by Thomson...
	Montelukast indicated for seasonal allergic rhinitis. (New FDA-Approved Indication).: An article from: Internal Medicine News by Damian McNamara (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2003. The length of the article is 579 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Montelukast indicated for seasonal allergic rhinitis. (New FDA-Approved Indication). Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: March 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 5 Page: 44(1) Article Type: Product/Service Evaluation Distributed by Thomson...
	Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial.(WASHINGTON WHISPERS): An article from: Journal of Drugs in Dermatology by Thomson Gale (Publisher) This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on September 1, 2005. The length of the article is 613 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial.(WASHINGTON WHISPERS) Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: September 1, 2005 Publisher: Thomson Gale Volume: 4 Issue: 5 Page: 659(1) Distributed by Thomson...
	Montelukast outcomes appear equal to fluticasone: persistent asthma.(Clinical Rounds): An article from: Internal Medicine News by Timothy F. Kirn (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on November 1, 2003. The length of the article is 565 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Montelukast outcomes appear equal to fluticasone: persistent asthma.(Clinical Rounds) Author: Timothy F. Kirn Publication: Internal Medicine News (Magazine/Journal) Date: November 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 21 Page: 18(1) Distributed by Thomson...
	Montelukast appears protective against effects of cat allergen.(Upper, Lower Airway Symptoms): An article from: Internal Medicine News by Robert Finn (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2004. The length of the article is 458 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Montelukast appears protective against effects of cat allergen.(Upper, Lower Airway Symptoms) Author: Robert Finn Publication: Internal Medicine News (Magazine/Journal) Date: May 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 10 Page: 12(1) Distributed by Thomson...
	Responses similar for montelukast and fluticasone.(Clinical Rounds): An article from: Skin & Allergy News by Debra Wood (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on August 1, 2004. The length of the article is 773 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Responses similar for montelukast and fluticasone.(Clinical Rounds) Author: Debra Wood Publication: Skin & Allergy News (Magazine/Journal) Date: August 1, 2004 Publisher: International Medical News Group Volume: 35 Issue: 8 Page: 54(1) Distributed by Thomson...
	Leukotriene Antagonists: Montelukast, Zafirlukast, Amlexanox, Pranlukast, Ablukast by Books LLC (Creator) Purchase includes free access to book updates online and a free trial membership in the publisher's book club where you can select from more than a million books without charge. Not illustrated. Excerpt: Montelukast (trade name Singulair) is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast is a CysLT1 antagonist; that is it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the...